Survival and complications in thalassemia

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 40-47

  Borgna Pignatti, Caterina ^a   Cappellini, M D ^b   De Stefano, P ^c   Del Vecchio, G C ^d   Forni, G L ^e   Gamberini, M R ^f   Ghilardi, R ^b   Origa, R ^g   Piga, A ^h   Romeo, M A ⁱ   Zhao, H ^j   Cnaan, A ^j  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^g UNIVERSITY OF CAGLIARI   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF CATANIA   (Italy)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Causes of death; Chelation; Hemosiderosis; Mortality; Survival; Thalassemia

Indexed keywords

HEPATITIS C ANTIBODY;

BLOOD TRANSFUSION; CAUSE OF DEATH; CONFERENCE PAPER; DIABETES MELLITUS; FRANCE; HEART DISEASE; HEART FAILURE; HEPATITIS; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INDIA; IRON OVERLOAD; ITALY; LIFE EXPECTANCY; LIVER CELL CARCINOMA; MORBIDITY; MORTALITY; OSTEOPENIA; OSTEOPOROSIS; QUALITY OF LIFE; SURVIVAL RATE; THALASSEMIA MAJOR; UNITED KINGDOM; UNITED STATES;

HEPATITIS C VIRUS;

EID: 29744459415     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.006     Document Type: Conference Paper

References (20)

1. THOMAS, E.D., C.D. BUCKNER, J.E. SANDERS, et al. 1982. Marrow transplantation for thalassaemia. Lancet 2: 227-229.
2. BORGNA-PINATTI, C., S. RUGOLOTTO, P. DE STEFANO, et al. 2004. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. 89: 1187-1193.
3. PRATI, D., A. ZANELLA, E. FARMA, et al. 1998. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 92: 3460-3464.
4. CUNNINGHAM, M.J., E.A. MACKLIN, E.J. NEUFELD & A.R. COHEN. 2004. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood 104: 34-39.
5. BORGNA PIGNATTI, C., G. VERGINE, T. LOMBARDO, et al. 2004. Hepatocellular carcinoma in the thalassemia syndromes. Br. J. Haematol. 124: 114-117.
6. MANCUSO, A., P. RIGANO, D. RENDA, et al. 2005. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalassemic. Am. J. Hematol. 78: 158-159.
7. BORGNA PIGNATTI, C., V. CARNELLI, V. CARUSO, et al. 1998. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 99: 76-79.
8. ELDOR, A., R. DURST, E. HY-AM, et al. 1999. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br. J. Haematol. 107: 739-746.
9. CAPPELLINI, M.D., L. ROBBIOLO, B.M. BOTTASSO, et al. 2000. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br. J. Haematol. 111: 467-473.
10. SKORDIS, N., S. CHRISTOU, M. KOLIOU, et al. 1998. Fertility in female patients with thalassemia. J. Pediatr. Endocrinol. Metab. 11: 935-943.
11. ANGASTINIOTIS, M., N. PAVLIDES, K. ARISTIDOU, et al. 1998. Bone pain in thalassaemia: assessment of DEXA and MRI findings. J. Pediatr. Endocrinol. Metab. 11: 779-784.
12. JENSEN, C.E., S.M. TUCK, J.E. AGNEW, et al. 1998. High incidence of osteoporosis in thalassaemia major. J. Pediatr. Endocrinol. Metab. 11: 975-977.
13. MODELL, B., M. KHAN & M. DARLISON. 2000. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 355: 2051-2052.
14. PIGA, A., F. LONGO, A. CONSOLATI, et al. 1997. Mortality and morbidity in thalassemia with conventional treatment. Third International Conference on Bone Marrow Transplantation in Thalassemia. Bone Marrow Transplant. 19: 11-13.
15. ANDERSON, L.J., B. WONKE, E. PRESCOTT, et al. 2002. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360: 516-520.
16. PENNELL, D.J., U.P. SECHTEM, C.B. HIGGINS, et al. 2004. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. J. Cardiovasc. Magn. Reson. 6: 727-765.
17. HERSHKO, C., G. LINK, A.M. KONIJN, et al. 2002. The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J. Lab. Clin. Med. 139: 50-58.
18. PIGA, A., C. GAGLIOTI, E. FOGLIACCO & F. TRICTA. 2003. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88: 489-496.
19. HERSHKO, C., M.D. CAPPELLINI, R. GALANELLO, et al. 2004. Purging iron from the heart. Br. J. Haematol. 125: 545-551.
20. ORIGA, R., E. FIUMANA, M.R. GAMBERINI, et al. 2005. Osteoporosis in β-thalassemia: clinical and genetic aspects. Ann. N.Y. Acad. Sci. 1054: 451-456.